ClinicalTrials.gg
CompletedNCT02215109Updated Aug 30, 2016

Retinal Vessel Diameter in Branch Retinal Vein Occlusion

An observational study in Branch Retinal Vein Occlusion, sponsored by Kyungpook National University Hospital. Completed at 1 site in South Korea. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-08-30.

Sponsored by Kyungpook National University Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
25
Ages
40 Years to 85 Years
Sex
All
01

Study summary

The authors investigated the consecutive change of retinal vessel's diameter in affected eye and fellow eye of Branch Retinal Vein Occlusion.

Read the detailed description

Twenty five consecutive patients who had undergone intravitreal bevacizumab injection for Branch Retinal Vein Occlusion with macular edema were included in this study. All subjects were enrolled between April, 2012 and April, 2013 in the Department of Ophthalmology, Kyungpook National University Hospital.

02

Conditions studied

  • Branch Retinal Vein Occlusion
03

In context

Retinal Vein Occlusion

291 studies on the registry are indexed under Retinal Vein Occlusion; 29 are open to participants now.

This study's enrollment of 25 is below the median of 126 across 65 observational studies indexed under Retinal Vein Occlusion.

Browse Retinal Vein Occlusion studies →

Lead sponsor

Kyungpook National University Hospital is the lead sponsor of 80 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A total of 25 patients will be included. All subjects with branch retinal vein occlusion scheduled for intravitreal bevacizumab injection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Best-corrected visual acuity less than 20/40
  • Central subfield macular thickness (CSMT) 300 μm or greater on spectral-domain optical coherence tomography

Exclusion criteria

Exclusion Criteria:

  • Patients with recurrent BRVO
  • History of previous treatments for BRVO including vitreoretinal surgery, intravitreal injection, subtenon injection or laser photocoagulation
  • Patients with diabetes or dyslipidemia
  • IOP ≥ 22mmHg, treatment for glaucoma, a family history of glaucoma, or optic neuropathy
  • High myopia (\<-6 Diopters), high hyperopia (>6 Diopters) or a history of refractive surgeries
  • Co-existing retinal disease other than BRVO
  • Corneal diseases include ulcer, keratoconus and a history of corneal laceration
  • Cataract and other media opacities resulting in visual impairment or poor fundus images
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
25 participants (actual)
Patient registry
No

Groups and cohorts

  • BRVO, Retinal vessel diameter

    The retinal vessel diameter was measured Branch Retinal Vein Occlusion patients after intravitreal bevacizumab injection.

06

What researchers measure

Primary outcomes

  1. Unoccluded retinal vessel diameter of Branch Retinal Vein Occlusion

    To evaluate the change of unoccluded retinal vessel diameter in affected eye of Branch Retinal Vein Occlusion and unaffected fellow eye.

    Time frame: 0, 1, 3, and 6 months

07

Study locations

1 site
  • Dong Ho Park
    Daegu, Kyungsangpookdo 700-721, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jul 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2014
First posted
Aug 13, 2014
Start
Apr 2012
Primary completionActual
Jul 2016
CompletionActual
Aug 2016
Last update
Aug 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02215109
Lead sponsor
Kyungpook National University Hospital
Responsible party
Dong Ho Park (Clinical professor, Kyungpook National University Hospital) — Principal investigator
First posted
Aug 13, 2014
Start date
Apr 2012
Primary completion
Jul 2016
Completion
Aug 2016
Last update
Aug 30, 2016

Study contacts

Dong Ho Park, M.D.
principal investigator · Kyungpook National University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion